Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal...
4 insider purchases on record · latest filing 2026-02-26.
Insiders have also filed 74 sale transactions at BCAX.